08 nov: Aktier/åbning: ISS og Lundbeck får kursklø efter regnskaber
08 nov: TDC indgår samarbejde med energiselskab
08-11-2017 09:30:23

AroCell AB: Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

Relateret indhold

AroCell AB (publ) announces today that the abstract entitled: "Quantification of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentrations (sTK1)", by B Tribukait et al was published today by the ESMO Asia congress organizers (

https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/session/calendar?q=Tribukait

).

The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery. Serum TK1 levels correlated to clinical/radiologically determined tumor response after cycles 2, 4 and 6, as well as pathologically determined response and disease-free survival. (To read the full abstract, please visit the ESMO Asia 2017 website.)

The investigators found that serum TK1 levels measured at the base-line and after completion of four cycles of treatment correlated significantly with clinical/radiological response during treatment and tumor-status at surgery. "This study shows that the reduction of tumor size and response to therapy can be assessed with our TK 210 ELISA" says Jan Stålemark, AroCell CEO. "Our product TK 210 ELISA was used in this study to investigate whether or not TK1 concentration can be a significant predictor of treatment response during chemotherapy of breast cancer. This is another study showing that serum TK1 measured with TK 210 ELISA is a promising biomarker for monitoring treatment response and possibly as a tool in clinical drug development. It gives a prompt signal on whether the new therapy works or not".

For additional information:

Jan Stålemark, CEO

AroCell AB (publ)

Tel: +46(0)706926206

info@arocell.com

www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark,

at 09:30 CET on 08 November 2017.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see

www.arocell.com

. Redeye AB is AroCell's Certified Adviser.

AroCell press release Final Nov 8 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: AroCell AB via Globenewswire

Vedhæftet fil: 823952.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Rockwool køber resten af mindre schweizisk selskab

17-11-2017 15:05:59
Rockwool har overtaget ejerskabet af den schweiziske isoleringsproducent Flumroc.Rockwool og Flumroc har haft en samarbejdsaftale siden 1969, og dengang købte det danske selskab en mindre aktiepost, som siden er øget til 43,5 pct.Fredag har det danske selskab købt de resterende aktier i selskabet, oplyser Rockwool i en pressemeddelelse.Flumroc har 230 ansatte og en årlig omsætning på omkring 67 mi..

Vestas: Britisk selskab investerer flere millioner på kursfald

17-11-2017 14:33:34
Det britiske investeringsselskab Marshall Wace har øget sit sats på kursfald i Vestas-aktien til en shortposition på 1,22 pct., hvilket i kroner og ører svarer 1,1 mia. kr.Tidligere lå positionen på 1,14 pct., viser indberetninger til Finanstilsynet.Vestas kom i sidste uge med et regnskab for tredje kvartal, som var præget af en intensivering af konkurrencen, hvilket har skabt usikkerhed om indtje..

Aktier/middag: Vestas og Mærsk trækker C20 Cap i rødt

17-11-2017 11:33:13
Stemningen er overvejende negativ på det danske aktiemarked fredag formiddag, hvor langt størstedelen af eliteaktierne i C20 Cap-indekset er på retur. Særligt Vestas og Mærsk-aktierne er presset i bund.Dermed kommer markedet igen ned på jorden efter to dage i streg med stigninger - og en endog ret stor en af slagsen torsdag.C20 Cap-indekset falder med 0,6 pct. til 1121,62, og ser man på hele ugen ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

AroCell AB (publ) 5,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. november 2017 20:43:37
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171108.1 - EUROWEB2 - 2017-11-18 20:43:37 - 2017-11-18 20:43:37 - 1 - Website: OKAY